25 XP   0   0   10

Alkem Laboratories Limited
Buy, Hold or Sell?

Let's analyse Alkem Laboratories Limited together

PenkeI guess you are interested in Alkem Laboratories Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alkem Laboratories Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alkem Laboratories Limited

I send you an email if I find something interesting about Alkem Laboratories Limited.

Quick analysis of Alkem Laboratories Limited (30 sec.)










What can you expect buying and holding a share of Alkem Laboratories Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR2.13
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR789.11
Expected worth in 1 year
INR985.71
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR373.75
Return On Investment
7.9%

For what price can you sell your share?

Current Price per Share
INR4,745.70
Expected price per share
INR3,609 - INR5,095
How sure are you?
50%

1. Valuation of Alkem Laboratories Limited (5 min.)




Live pricePrice per Share (EOD)

INR4,745.70

Intrinsic Value Per Share

INR573.15 - INR2,317.38

Total Value Per Share

INR1,362.26 - INR3,106.49

2. Growth of Alkem Laboratories Limited (5 min.)




Is Alkem Laboratories Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$1.1b$1b$70.5m6.2%

How much money is Alkem Laboratories Limited making?

Current yearPrevious yearGrowGrow %
Making money$118.1m$197.4m-$79.3m-67.2%
Net Profit Margin8.5%15.7%--

How much money comes from the company's main activities?

3. Financial Health of Alkem Laboratories Limited (5 min.)




What can you expect buying and holding a share of Alkem Laboratories Limited? (5 min.)

Welcome investor! Alkem Laboratories Limited's management wants to use your money to grow the business. In return you get a share of Alkem Laboratories Limited.

What can you expect buying and holding a share of Alkem Laboratories Limited?

First you should know what it really means to hold a share of Alkem Laboratories Limited. And how you can make/lose money.

Speculation

The Price per Share of Alkem Laboratories Limited is INR4,746. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alkem Laboratories Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alkem Laboratories Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR789.11. Based on the TTM, the Book Value Change Per Share is INR49.15 per quarter. Based on the YOY, the Book Value Change Per Share is INR107.83 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR44.29 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alkem Laboratories Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.990.0%0.990.0%1.650.0%1.220.0%0.920.0%
Usd Book Value Change Per Share0.590.0%0.590.0%1.290.0%0.890.0%0.710.0%
Usd Dividend Per Share0.530.0%0.530.0%0.420.0%0.390.0%0.250.0%
Usd Total Gains Per Share1.120.0%1.120.0%1.720.0%1.280.0%0.960.0%
Usd Price Per Share40.75-40.75-43.45-33.27-23.30-
Price to Earnings Ratio41.26-41.26-26.31-28.13-22.98-
Price-to-Total Gains Ratio36.35-36.35-25.30-26.44-27.30-
Price to Book Ratio4.30-4.30-4.89-4.35-3.68-
Price-to-Total Gains Ratio36.35-36.35-25.30-26.44-27.30-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share56.9484
Number of shares17
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.530.39
Usd Book Value Change Per Share0.590.89
Usd Total Gains Per Share1.121.28
Gains per Quarter (17 shares)19.0621.82
Gains per Year (17 shares)76.2587.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1364066276177
2728014253121164
310812021880182251
4145160294106243338
5181201370133304425
6217241446159364512
7253281522186425599
8289321598212486686
9325361674239547773
10361401750265607860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%14.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%14.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%14.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%14.00.00.0100.0%

Fundamentals of Alkem Laboratories Limited

About Alkem Laboratories Limited

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India.

Fundamental data was last updated by Penke on 2024-04-13 20:18:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Alkem Laboratories Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alkem Laboratories Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Alkem Laboratories Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 8.5% means that ₹0.08 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alkem Laboratories Limited:

  • The MRQ is 8.5%. The company is making a profit. +1
  • The TTM is 8.5%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ8.5%TTM8.5%0.0%
TTM8.5%YOY15.7%-7.2%
TTM8.5%5Y13.3%-4.8%
5Y13.3%10Y13.3%+0.0%
1.1.2. Return on Assets

Shows how efficient Alkem Laboratories Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alkem Laboratories Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 7.2% Return on Assets means that Alkem Laboratories Limited generated ₹0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alkem Laboratories Limited:

  • The MRQ is 7.2%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.2%TTM7.2%0.0%
TTM7.2%YOY11.7%-4.5%
TTM7.2%5Y10.6%-3.5%
5Y10.6%10Y10.5%+0.1%
1.1.3. Return on Equity

Shows how efficient Alkem Laboratories Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alkem Laboratories Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 10.9% Return on Equity means Alkem Laboratories Limited generated ₹0.11 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alkem Laboratories Limited:

  • The MRQ is 10.9%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 10.9%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ10.9%TTM10.9%0.0%
TTM10.9%YOY19.1%-8.2%
TTM10.9%5Y16.7%-5.9%
5Y16.7%10Y16.5%+0.3%

1.2. Operating Efficiency of Alkem Laboratories Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alkem Laboratories Limited is operating .

  • Measures how much profit Alkem Laboratories Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alkem Laboratories Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 13.1% means the company generated ₹0.13  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alkem Laboratories Limited:

  • The MRQ is 13.1%. The company is operating less efficient.
  • The TTM is 13.1%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ13.1%TTM13.1%0.0%
TTM13.1%YOY18.0%-4.9%
TTM13.1%5Y16.4%-3.3%
5Y16.4%10Y16.7%-0.3%
1.2.2. Operating Ratio

Measures how efficient Alkem Laboratories Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.89 means that the operating costs are ₹0.89 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Alkem Laboratories Limited:

  • The MRQ is 0.888. The company is less efficient in keeping operating costs low.
  • The TTM is 0.888. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.888TTM0.8880.000
TTM0.888YOY0.833+0.055
TTM0.8885Y0.849+0.039
5Y0.84910Y0.855-0.006

1.3. Liquidity of Alkem Laboratories Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alkem Laboratories Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.35 means the company has ₹2.35 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Alkem Laboratories Limited:

  • The MRQ is 2.355. The company is able to pay all its short-term debts. +1
  • The TTM is 2.355. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.355TTM2.3550.000
TTM2.355YOY1.755+0.599
TTM2.3555Y1.930+0.424
5Y1.93010Y1.767+0.163
1.3.2. Quick Ratio

Measures if Alkem Laboratories Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alkem Laboratories Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.22 means the company can pay off ₹2.22 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alkem Laboratories Limited:

  • The MRQ is 2.222. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.222. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.222TTM2.2220.000
TTM2.222YOY1.350+0.872
TTM2.2225Y1.497+0.725
5Y1.49710Y1.342+0.155

1.4. Solvency of Alkem Laboratories Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alkem Laboratories Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alkem Laboratories Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.31 means that Alkem Laboratories Limited assets are financed with 31.4% credit (debt) and the remaining percentage (100% - 31.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alkem Laboratories Limited:

  • The MRQ is 0.314. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.314. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.314TTM0.3140.000
TTM0.314YOY0.371-0.057
TTM0.3145Y0.343-0.029
5Y0.34310Y0.346-0.003
1.4.2. Debt to Equity Ratio

Measures if Alkem Laboratories Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alkem Laboratories Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 47.8% means that company has ₹0.48 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alkem Laboratories Limited:

  • The MRQ is 0.478. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.478. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.478TTM0.4780.000
TTM0.478YOY0.605-0.127
TTM0.4785Y0.539-0.061
5Y0.53910Y0.547-0.008

2. Market Valuation of Alkem Laboratories Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Alkem Laboratories Limited generates.

  • Above 15 is considered overpriced but always compare Alkem Laboratories Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 41.26 means the investor is paying ₹41.26 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alkem Laboratories Limited:

  • The EOD is 57.655. Based on the earnings, the company is expensive. -2
  • The MRQ is 41.259. Based on the earnings, the company is overpriced. -1
  • The TTM is 41.259. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD57.655MRQ41.259+16.396
MRQ41.259TTM41.2590.000
TTM41.259YOY26.307+14.952
TTM41.2595Y28.132+13.127
5Y28.13210Y22.976+5.156
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alkem Laboratories Limited:

  • The EOD is 39.143. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 28.012. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 28.012. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD39.143MRQ28.012+11.132
MRQ28.012TTM28.0120.000
TTM28.012YOY56.066-28.054
TTM28.0125Y64.925-36.914
5Y64.92510Y20.504+44.421
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alkem Laboratories Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 4.30 means the investor is paying ₹4.30 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Alkem Laboratories Limited:

  • The EOD is 6.014. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.304. Based on the equity, the company is fair priced.
  • The TTM is 4.304. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD6.014MRQ4.304+1.710
MRQ4.304TTM4.3040.000
TTM4.304YOY4.893-0.589
TTM4.3045Y4.349-0.045
5Y4.34910Y3.677+0.672
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Alkem Laboratories Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--49.15149.1510%107.834-54%74.431-34%59.059-17%
Book Value Per Share--789.111789.1110%739.960+7%630.975+25%474.747+66%
Current Ratio--2.3552.3550%1.755+34%1.930+22%1.767+33%
Debt To Asset Ratio--0.3140.3140%0.371-15%0.343-8%0.346-9%
Debt To Equity Ratio--0.4780.4780%0.605-21%0.539-11%0.547-13%
Dividend Per Share--44.28744.2870%35.287+26%32.524+36%21.087+110%
Eps--82.31382.3130%137.634-40%102.077-19%76.894+7%
Free Cash Flow Per Share--121.239121.2390%64.579+88%62.927+93%31.101+290%
Free Cash Flow To Equity Per Share---26.030-26.0300%96.325-127%30.263-186%5.689-558%
Gross Profit Margin---0.336-0.3360%0.363-193%0.183-284%0.157-314%
Intrinsic Value_10Y_max--2317.383--------
Intrinsic Value_10Y_min--573.146--------
Intrinsic Value_1Y_max--122.324--------
Intrinsic Value_1Y_min--38.127--------
Intrinsic Value_3Y_max--451.286--------
Intrinsic Value_3Y_min--131.956--------
Intrinsic Value_5Y_max--881.223--------
Intrinsic Value_5Y_min--244.136--------
Market Cap567419620500.000+28%406054696500.000406054696500.0000%432908995500.000-6%331513092900.000+22%232111534500.000+75%
Net Profit Margin--0.0850.0850%0.157-46%0.133-36%0.133-36%
Operating Margin--0.1310.1310%0.180-27%0.164-20%0.167-22%
Operating Ratio--0.8880.8880%0.833+7%0.849+5%0.855+4%
Pb Ratio6.014+28%4.3044.3040%4.893-12%4.349-1%3.677+17%
Pe Ratio57.655+28%41.25941.2590%26.307+57%28.132+47%22.976+80%
Price Per Share4745.700+28%3396.1003396.1000%3620.700-6%2772.660+22%1941.300+75%
Price To Free Cash Flow Ratio39.143+28%28.01228.0120%56.066-50%64.925-57%20.504+37%
Price To Total Gains Ratio50.790+28%36.34636.3460%25.298+44%26.438+37%27.296+33%
Quick Ratio--2.2222.2220%1.350+65%1.497+48%1.342+66%
Return On Assets--0.0720.0720%0.117-39%0.106-33%0.105-32%
Return On Equity--0.1090.1090%0.191-43%0.167-35%0.165-34%
Total Gains Per Share--93.43893.4380%143.121-35%106.955-13%80.146+17%
Usd Book Value--1132200000.0001132200000.0000%1061679600.000+7%905310240.000+25%681159982.800+66%
Usd Book Value Change Per Share--0.5900.5900%1.294-54%0.893-34%0.709-17%
Usd Book Value Per Share--9.4699.4690%8.880+7%7.572+25%5.697+66%
Usd Dividend Per Share--0.5310.5310%0.423+26%0.390+36%0.253+110%
Usd Eps--0.9880.9880%1.652-40%1.225-19%0.923+7%
Usd Free Cash Flow--173950800.000173950800.0000%92656800.000+88%90287040.000+93%44623023.600+290%
Usd Free Cash Flow Per Share--1.4551.4550%0.775+88%0.755+93%0.373+290%
Usd Free Cash Flow To Equity Per Share---0.312-0.3120%1.156-127%0.363-186%0.068-558%
Usd Market Cap6809035446.000+28%4872656358.0004872656358.0000%5194907946.000-6%3978157114.800+22%2785338414.000+75%
Usd Price Per Share56.948+28%40.75340.7530%43.448-6%33.272+22%23.296+75%
Usd Profit--118100400.000118100400.0000%197474400.000-40%146457360.000-19%109610080.800+8%
Usd Revenue--1391911200.0001391911200.0000%1261443600.000+10%1111140000.000+25%835491699.600+67%
Usd Total Gains Per Share--1.1211.1210%1.717-35%1.283-13%0.962+17%
 EOD+4 -4MRQTTM+0 -0YOY+17 -195Y+19 -1710Y+22 -14

3.2. Fundamental Score

Let's check the fundamental score of Alkem Laboratories Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1557.655
Price to Book Ratio (EOD)Between0-16.014
Net Profit Margin (MRQ)Greater than00.085
Operating Margin (MRQ)Greater than00.131
Quick Ratio (MRQ)Greater than12.222
Current Ratio (MRQ)Greater than12.355
Debt to Asset Ratio (MRQ)Less than10.314
Debt to Equity Ratio (MRQ)Less than10.478
Return on Equity (MRQ)Greater than0.150.109
Return on Assets (MRQ)Greater than0.050.072
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Alkem Laboratories Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4,644.250
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets137,566,500
Total Liabilities43,216,500
Total Stockholder Equity90,452,900
 As reported
Total Liabilities 43,216,500
Total Stockholder Equity+ 90,452,900
Total Assets = 137,566,500

Assets

Total Assets137,566,500
Total Current Assets87,296,800
Long-term Assets50,269,700
Total Current Assets
Cash And Cash Equivalents 2,738,000
Short-term Investments 28,500,500
Net Receivables 22,622,100
Inventory 26,075,300
Other Current Assets 7,360,900
Total Current Assets  (as reported)87,296,800
Total Current Assets  (calculated)87,296,800
+/-0
Long-term Assets
Property Plant Equipment 25,135,300
Goodwill 4,131,700
Intangible Assets 793,900
Other Assets 13,422,500
Long-term Assets  (as reported)50,269,700
Long-term Assets  (calculated)43,483,400
+/- 6,786,300

Liabilities & Shareholders' Equity

Total Current Liabilities37,071,500
Long-term Liabilities6,145,000
Total Stockholder Equity90,452,900
Total Current Liabilities
Short-term Debt 13,263,500
Short Long Term Debt 13,071,500
Accounts payable 11,650,300
Other Current Liabilities 1,868,900
Total Current Liabilities  (as reported)37,071,500
Total Current Liabilities  (calculated)39,854,200
+/- 2,782,700
Long-term Liabilities
Long term Debt Total 703,300
Capital Lease Obligations 895,300
Long-term Liabilities Other 88,000
Long-term Liabilities  (as reported)6,145,000
Long-term Liabilities  (calculated)1,686,600
+/- 4,458,400
Total Stockholder Equity
Common Stock239,100
Retained Earnings 70,519,700
Other Stockholders Equity 19,694,100
Total Stockholder Equity (as reported)90,452,900
Total Stockholder Equity (calculated)90,452,900
+/-0
Other
Capital Stock239,100
Cash And Equivalents747,000
Cash and Short Term Investments 31,238,500
Common Stock Shares Outstanding 119,565
Current Deferred Revenue10,288,800
Liabilities and Stockholders Equity 137,566,500
Net Debt 11,228,800
Net Invested Capital 103,524,400
Net Tangible Assets 85,527,400
Net Working Capital 50,225,300
Property Plant and Equipment Gross 25,135,300
Short Long Term Debt Total 13,966,800



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-31
> Total Assets 
15,593,446
26,534,056
31,823,974
40,482,045
42,320,703
52,957,600
54,386,700
65,680,500
76,656,300
82,081,900
99,433,300
115,192,600
140,691,900
137,566,500
137,566,500140,691,900115,192,60099,433,30082,081,90076,656,30065,680,50054,386,70052,957,60042,320,70340,482,04531,823,97426,534,05615,593,446
   > Total Current Assets 
11,391,721
21,099,803
21,775,356
26,937,123
22,086,021
23,380,500
27,061,600
29,007,200
39,151,900
42,161,300
54,960,300
69,288,200
84,354,300
87,296,800
87,296,80084,354,30069,288,20054,960,30042,161,30039,151,90029,007,20027,061,60023,380,50022,086,02126,937,12321,775,35621,099,80311,391,721
       Cash And Cash Equivalents 
6,615,556
14,648,694
11,308,371
4,300,084
281,387
1,396,000
1,270,700
1,666,300
1,667,100
2,490,500
1,759,400
1,742,200
2,321,800
2,738,000
2,738,0002,321,8001,742,2001,759,4002,490,5001,667,1001,666,3001,270,7001,396,000281,3874,300,08411,308,37114,648,6946,615,556
       Short-term Investments 
0
0
3,221,998
13,028,864
11,936,277
2,098,400
2,608,500
5,106,000
6,578,100
6,403,500
2,843,500
15,794,800
10,808,500
28,500,500
28,500,50010,808,50015,794,8002,843,5006,403,5006,578,1005,106,0002,608,5002,098,40011,936,27713,028,8643,221,99800
       Net Receivables 
0
0
0
0
4,138,900
5,811,400
5,675,100
8,752,300
12,751,600
14,886,600
19,109,500
28,463,000
40,942,000
22,622,100
22,622,10040,942,00028,463,00019,109,50014,886,60012,751,6008,752,3005,675,1005,811,4004,138,9000000
       Inventory 
1,757,039
2,279,187
2,971,322
4,428,546
5,045,533
7,842,300
9,094,300
12,060,000
14,421,900
14,998,700
18,188,200
23,124,400
30,055,300
26,075,300
26,075,30030,055,30023,124,40018,188,20014,998,70014,421,90012,060,0009,094,3007,842,3005,045,5334,428,5462,971,3222,279,1871,757,039
       Other Current Assets 
3,019,126
4,171,922
4,273,665
5,179,629
4,822,824
12,043,800
14,088,100
10,174,900
16,484,800
3,382,000
32,169,200
163,800
226,700
7,360,900
7,360,900226,700163,80032,169,2003,382,00016,484,80010,174,90014,088,10012,043,8004,822,8245,179,6294,273,6654,171,9223,019,126
   > Long-term Assets 
4,201,725
5,434,253
10,048,618
13,544,922
20,234,682
29,577,100
27,325,100
36,673,300
37,504,400
39,920,600
44,473,000
45,904,400
56,337,600
50,269,700
50,269,70056,337,60045,904,40044,473,00039,920,60037,504,40036,673,30027,325,10029,577,10020,234,68213,544,92210,048,6185,434,2534,201,725
       Property Plant Equipment 
4,004,866
4,901,949
6,633,947
8,278,317
9,055,725
10,833,400
12,043,700
16,937,100
22,542,600
25,985,600
26,692,400
26,271,900
26,265,600
25,135,300
25,135,30026,265,60026,271,90026,692,40025,985,60022,542,60016,937,10012,043,70010,833,4009,055,7258,278,3176,633,9474,901,9494,004,866
       Goodwill 
0
0
0
0
1,903,400
3,535,400
3,799,300
3,658,800
3,664,400
3,805,600
3,984,500
3,953,900
4,030,900
4,131,700
4,131,7004,030,9003,953,9003,984,5003,805,6003,664,4003,658,8003,799,3003,535,4001,903,4000000
       Long Term Investments 
0
0
0
0
11,062,900
7,325,700
1,221,400
4,544,600
1,487,500
1,077,700
0
0
0
0
00001,077,7001,487,5004,544,6001,221,4007,325,70011,062,9000000
       Intangible Assets 
0
0
0
182,040
38,167
481,500
297,000
367,100
438,700
442,700
2,032,900
1,636,600
2,115,400
793,900
793,9002,115,4001,636,6002,032,900442,700438,700367,100297,000481,50038,167182,040000
       Long-term Assets Other 
196,859
532,304
6,136,805
17,079,331
16,978,745
11,874,500
11,062,900
9,153,000
8,413,000
7,690,600
1,318,100
1,377,100
2,030,500
1,935,100
1,935,1002,030,5001,377,1001,318,1007,690,6008,413,0009,153,00011,062,90011,874,50016,978,74517,079,3316,136,805532,304196,859
> Total Liabilities 
3,540,169
11,455,666
12,768,695
16,743,390
14,420,784
22,110,600
18,394,800
19,851,800
26,803,100
26,362,400
36,343,600
39,612,500
52,218,600
43,216,500
43,216,50052,218,60039,612,50036,343,60026,362,40026,803,10019,851,80018,394,80022,110,60014,420,78416,743,39012,768,69511,455,6663,540,169
   > Total Current Liabilities 
2,542,705
3,829,589
10,790,088
15,007,463
12,995,644
20,059,800
15,323,500
16,624,000
23,833,100
21,902,200
32,433,100
36,040,500
48,053,400
37,071,500
37,071,50048,053,40036,040,50032,433,10021,902,20023,833,10016,624,00015,323,50020,059,80012,995,64415,007,46310,790,0883,829,5892,542,705
       Short-term Debt 
0
0
6,763,501
11,467,107
9,024,056
12,724,900
5,342,800
4,505,800
8,668,300
7,127,700
15,634,300
16,943,400
25,923,400
13,263,500
13,263,50025,923,40016,943,40015,634,3007,127,7008,668,3004,505,8005,342,80012,724,9009,024,05611,467,1076,763,50100
       Short Long Term Debt 
0
0
0
0
11,332,200
1,439,200
698,700
4,505,800
8,668,300
7,127,700
15,416,100
16,359,600
25,707,400
13,071,500
13,071,50025,707,40016,359,60015,416,1007,127,7008,668,3004,505,800698,7001,439,20011,332,2000000
       Accounts payable 
1,694,844
2,357,579
2,624,136
2,575,405
2,760,402
4,619,200
5,792,800
7,413,700
9,607,100
9,622,500
9,540,500
10,694,100
11,733,800
11,650,300
11,650,30011,733,80010,694,1009,540,5009,622,5009,607,1007,413,7005,792,8004,619,2002,760,4022,575,4052,624,1362,357,5791,694,844
       Other Current Liabilities 
847,861
1,472,010
1,402,451
964,951
1,211,186
2,715,700
4,187,900
4,581,900
5,384,200
5,130,900
22,905,300
1,193,400
1,503,200
1,868,900
1,868,9001,503,2001,193,40022,905,3005,130,9005,384,2004,581,9004,187,9002,715,7001,211,186964,9511,402,4511,472,010847,861
   > Long-term Liabilities 
997,464
7,626,077
1,978,607
1,735,927
1,425,140
2,050,800
3,071,300
3,227,800
2,970,000
4,460,200
3,910,500
3,572,000
4,165,200
6,145,000
6,145,0004,165,2003,572,0003,910,5004,460,2002,970,0003,227,8003,071,3002,050,8001,425,1401,735,9271,978,6077,626,077997,464
       Long term Debt Total 
0
0
0
0
0
0
1,234,600
1,815,600
1,307,300
2,313,000
1,592,400
976,400
758,500
703,300
703,300758,500976,4001,592,4002,313,0001,307,3001,815,6001,234,600000000
       Other Liabilities 
0
0
0
0
916,300
1,665,100
866,200
1,139,300
1,662,700
1,874,100
2,318,100
2,595,600
3,406,700
0
03,406,7002,595,6002,318,1001,874,1001,662,7001,139,300866,2001,665,100916,3000000
> Total Stockholder Equity
12,053,277
15,078,390
19,055,279
23,738,655
27,899,919
29,990,500
35,026,500
44,676,400
48,637,700
54,393,400
61,606,700
73,767,300
86,379,000
90,452,900
90,452,90086,379,00073,767,30061,606,70054,393,40048,637,70044,676,40035,026,50029,990,50027,899,91923,738,65519,055,27915,078,39012,053,277
   Common Stock
119,565
119,565
119,565
119,565
119,565
239,100
239,100
239,100
239,100
239,100
239,100
239,100
239,100
239,100
239,100239,100239,100239,100239,100239,100239,100239,100239,100119,565119,565119,565119,565119,565
   Retained Earnings 
928,475
2,453,588
4,430,477
0
25,610,600
29,588,000
36,534,100
24,818,700
28,784,300
34,223,200
41,165,100
53,667,500
65,938,900
70,519,700
70,519,70065,938,90053,667,50041,165,10034,223,20028,784,30024,818,70036,534,10029,588,00025,610,60004,430,4772,453,588928,475
   Accumulated Other Comprehensive Income 
-1,058,796
-1,319,624
-1,378,873
-1,690,934
-2,074,218
-3,247,300
-3,832,300
-1,581,400
-2,843,200
-4,419,300
-5,923,800
19,860,700
20,201,000
19,694,100
19,694,10020,201,00019,860,700-5,923,800-4,419,300-2,843,200-1,581,400-3,832,300-3,247,300-2,074,218-1,690,934-1,378,873-1,319,624-1,058,796
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 
12,064,033
13,824,861
15,884,110
25,310,024
29,854,572
32,998,700
38,619,700
21,200,000
22,457,500
24,350,400
-61,276,500
19,860,700
20,201,000
19,694,100
19,694,10020,201,00019,860,700-61,276,50024,350,40022,457,50021,200,00038,619,70032,998,70029,854,57225,310,02415,884,11013,824,86112,064,033



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue115,992,600
Cost of Revenue-49,068,400
Gross Profit66,924,20066,924,200
 
Operating Income (+$)
Gross Profit66,924,200
Operating Expense-53,933,900
Operating Income13,195,90012,990,300
 
Operating Expense (+$)
Research Development5,411,400
Selling General Administrative2,991,400
Selling And Marketing Expenses13,150,800
Operating Expense53,933,90021,553,600
 
Net Interest Income (+$)
Interest Income1,073,600
Interest Expense-1,073,600
Other Finance Cost-1,073,600
Net Interest Income-1,073,600
 
Pretax Income (+$)
Operating Income13,195,900
Net Interest Income-1,073,600
Other Non-Operating Income Expenses0
Income Before Tax (EBT)13,047,70013,344,100
EBIT - interestExpense = 14,077,500
12,821,300
10,915,300
Interest Expense1,073,600
Earnings Before Interest and Taxes (EBIT)15,151,10014,121,300
Earnings Before Interest and Taxes (EBITDA)18,255,300
 
After tax Income (+$)
Income Before Tax13,047,700
Tax Provision-2,979,600
Net Income From Continuing Ops10,068,10010,068,100
Net Income9,841,700
Net Income Applicable To Common Shares9,841,700
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses103,002,300
Total Other Income/Expenses Net-148,2001,073,600
 

Technical Analysis of Alkem Laboratories Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alkem Laboratories Limited. The general trend of Alkem Laboratories Limited is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alkem Laboratories Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alkem Laboratories Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 4,650 < 5,059 < 5,095.

The bearish price targets are: 4,114 > 3,685 > 3,609.

Tweet this
Alkem Laboratories Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alkem Laboratories Limited. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alkem Laboratories Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Moving Average Convergence/Divergence (MACD) ChartAlkem Laboratories Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alkem Laboratories Limited. The current adx is .

Alkem Laboratories Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Relative Strength Index (RSI) ChartAlkem Laboratories Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Stochastic Oscillator ChartAlkem Laboratories Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Commodity Channel Index (CCI) ChartAlkem Laboratories Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Chande Momentum Oscillator (CMO) ChartAlkem Laboratories Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Williams %R ChartAlkem Laboratories Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Average True Range (ATR) ChartAlkem Laboratories Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily On-Balance Volume (OBV) ChartAlkem Laboratories Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alkem Laboratories Limited.

Alkem Laboratories Limited Daily Money Flow Index (MFI) ChartAlkem Laboratories Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alkem Laboratories Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Alkem Laboratories Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alkem Laboratories Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4,644.250
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alkem Laboratories Limited with someone you think should read this too:
  • Are you bullish or bearish on Alkem Laboratories Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alkem Laboratories Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alkem Laboratories Limited

I send you an email if I find something interesting about Alkem Laboratories Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Alkem Laboratories Limited.

Receive notifications about Alkem Laboratories Limited in your mailbox!